February 2, 2017 07:30 AM EST
Pharma

Cy­to­ki­net­ics chief Blum grabs $100M roy­al­ty deal to fund an ex­pand­ed mar­ket­ing plan for PhI­II heart drug

John Carroll

Editor & Founder

Cy­to­ki­net­ics CEO Robert Blum has struck a $100 mil­lion deal for a piece of the prospec­tive roy­al­ty stream for their heart drug ome­cam­tiv mecar­bil, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times